semaglutide news Ozempic cuts risk of death from kidney disease, major study finds Novo Nordisk wins EU approval

Published clinical-trial data and ongoing studies continue to evaluate its safety profile, including gastrointestinal tolerability, heart-rate changes, pancreatic and gallbladder-related events, kidney-related risks in the setting of dehydration, and other potential adverse events

We engage with major carriers like Aetna, Blue Cross Blue Shield, UnitedHealthcare, Cigna, and Medicaid to ascertain the coverage specifics for drugs like Wegovy and Zepbound

Lee Kaplan, an associate professor with Harvard Medical School

Hayfever Search Something

Final thoughts There are a number of strategies that can be used to prevent muscle atrophy in your patients